Applied Therapeutics, Inc. (APLT)
$
0.49
-0.03 (-6.12%)
Key metrics
Financial statements
Free cash flow per share
-5.6698
Market cap
56.9 Million
Price to sales ratio
-269.6040
Debt to equity
0.3345
Current ratio
1.0569
Income quality
0.4369
Average inventory
0
ROE
-5.8337
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative products aimed at addressing cardiovascular diseases, galactosemia, and complications associated with diabetes. The company’s lead product candidate, AT-007, has successfully completed phase 1/2 trials for the treatment of galactosemia in healthy adults and is currently being evaluated in pediatric studies for the same condition. Furthermore, AT-007 is under investigation for treating sorbitol dehydrogenase deficiency and phosphomannomutase enzyme-CDG. In addition to AT-007, Applied Therapeutics is advancing AT-001, which is presently undergoing phase III clinical trials intended for diabetic cardiomyopathy and diabetic peripheral neuropathy. The company also has preclinical candidates, including AT-003 for diabetic retinopathy and AT-104, a PI3K inhibitor targeting T Cell Acute Lymphoblastic Leukemia in hematological oncology. As for its financial performance, the earnings per share (EPS) is reported at -$1.42 indicating the company's profitability on a per-share basis. The operating expenses amount to $74,528,000.00 encompassing various operational costs incurred. Furthermore, the company reported an income before tax of -$119,763,000.00 showcasing its pre-tax profitability. The diluted EPS stands at -$1.42 accounting for potential share dilution, while the net income ratio is -$11.98 reflecting the company's profitability margin. With a market capitalization of $56,886,448.00 Applied Therapeutics is classified as a small-cap player in the biopharmaceutical landscape. The stock is affordable at $0.50 making it suitable for budget-conscious investors. Additionally, the stock has a high average trading volume of 3,548,120.00 which indicates strong liquidity in the market. As a key player in the Biotechnology industry, the company contributes significantly to the overall market landscape, while belonging to the Healthcare sector, driving ongoing innovation and growth within the healthcare field.
What is Applied Therapeutics, Inc. (APLT)'s stock forecast?
Analysts predict Applied Therapeutics, Inc. stock to fluctuate between $0.43 (low) and $10.62 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Applied Therapeutics, Inc.'s market capitalization?
As of 2025-04-01, Applied Therapeutics, Inc.'s market cap is $56,886,448, based on 116,356,000 outstanding shares.
How does Applied Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Applied Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Applied Therapeutics, Inc. (APLT) stock?
To buy Applied Therapeutics, Inc. (APLT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for APLT. Place an order (Market, Limit, etc.).
What is the best time to invest in Applied Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Applied Therapeutics, Inc. perform in the last earnings report?
Revenue: $9,993,000 | EPS: -$1.42 | Growth: -34.26%.
Where can I find Applied Therapeutics, Inc.'s investor relations reports?
Visit https://www.appliedtherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Applied Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Applied Therapeutics, Inc. stock?
All-time high: $29.80 (2021-02-09) | All-time low: $0.43 (2025-03-04).
What are the key trends affecting Applied Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130443&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130340&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130271&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ:APLT) between January 3, 2024 and December 2, 2024, both dates inclusive (the "Class Period"), of the important February 18, 2025 lead plaintiff deadline. SO WHAT: If you purchased Applied Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130160&wire=1 or contact Joseph E. Levi, Esq.
prnewswire.com
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Applied Therapeutics investors who were adversely affected by alleged securities fraud between January 3, 2024 and December 2, 2024.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130109&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130095&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ:APLT) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130067&wire=1 or contact Joseph E. Levi, Esq.
See all news
